Search the Newsreel

Die Fresenius-Aktie steigt nach Prognoseanhebung und Rating-Aufwertung

VAML Share Price Today - Vedanta Aluminium Metal Stock Analysis

Goyal Aluminiums consolidated net profit rises 84.00% in the June 2026 quarter

DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’

Maan Aluminium Reports Utilisation of Preferential Issue Funds for June Quarter

Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake

Commodore Capital and related filers have disclosed a beneficial ownership of 2.41 million Common Shares, representing an 1.8% stake in Definium Therapeutics (DFTX) as of June 30, 2026. This position includes 2 million existing Common Shares and 410,000 shares acquirable through a pre-funded warrant. …

What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?

Definium Therapeutics (DFTX) reported positive Phase 3 results for DT120 ODT in generalized anxiety disorder (GAD), meeting primary and secondary efficacy endpoints. These results, which showed statistically significant and clinically meaningful benefits, are expected to support future regulatory filings for the drug. Investors are …

DFTX News Today | Why did Definium Therapeutics stock go down today?

Fresenius Medical Care stock steadies around $23 as investors weigh recent buybacks and guidance

Fresenius Medical Care stock is trading steadily around $23 in mid-August 2026, influenced by recent share buybacks and a modest year-to-date decline. The company's capital allocation strategy now includes renewed willingness for buybacks, alongside guidance for continued mid-single-digit revenue growth and improved operating income …

Why Mega Uranium Ltd. stock plummeted yesterday

Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36%

Driehaus Capital Management LLC has reduced its stake in Definium Therapeutics (DFTX) to 5.36% as of June 30, 2026, down from 6.64% reported on December 31, 2025. This ownership represents 6,845,276 shares of common stock, held in various client accounts managed by DCM. The …

Elevate Uranium (ASX:EL8) Gains as Namibian Uranium Story Attracts Interest

Vedanta Aluminium Metal Ltd. Share Price Today - Vedanta Aluminium Metal Ltd. Stock Price Live NSE/BSE

Xingfa Aluminium Sets Board Meeting to Review Interim Results and Dividend

Elevate Uranium slips to 24.5c as Marenica share settlement lands amid a busy run of project news

Die Fresenius-Aktie steigt nach erhöhter Prognose und Rückenwind von UBS

Maan Aluminium standalone net profit rises 13.55% in the June 2026 quarter

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

RBC Capital Markets highlighted that Definium Therapeutics' DT120 data from a Phase 2 proof-of-concept study, though not statistically significant, provides valuable insights into the drug's mechanisms and biomarkers. The firm believes this information significantly de-risks future trials, particularly the upcoming Phase 2b study which …

Orpheus Uranium Executes Sale Agreement to Acquire Adavale's Marree Embayment Uranium Portfolio

Orpheus Uranium to Expand Marree Footprint with Strategic Tenement Deal

Orpheus Uranium Expands Marree Footprint with Strategic Tenement Deal

Price to earnings ratio of Tuniu Corp. Sponsored ADR Class A – TRADEGATE:0TU

The article displays the price to earnings ratio for Tuniu Corp. Sponsored ADR Class A (TRADEGATE:0TU). It is presented through TradingView, indicating that the market is currently closed with no trades. The primary focus is on the financial metric, along with source and copyright …

Why Mega Uranium Ltd. stock is sliding today

Fresenius Medical Care stock holds steady near $24 as investors digest latest capital market update

Fresenius Medical Care stock is trading near $24, with a slight decline of 0.67% on the NYSE and 0.28% in Europe, as investors analyze the company's latest capital market update. This update details recent share repurchases and trading activity, suggesting a strategy to optimize …

Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company

Wells Fargo & Company has raised its price target for Definium Therapeutics (NASDAQ:DFTX) to $72.00 from $68.00, maintaining an "overweight" rating and suggesting a potential upside of 68.26%. This comes amid broadly positive analyst sentiment and recent positive Phase 3 clinical trial results for …

Uranium Royalty (UROY) Stock Looks Pricey On The Sweetwater Deal

Uranium Royalty (UROY) stock has seen a significant 100.5% return over the past three years, but current valuation checks suggest it is expensive, particularly with a P/E ratio of 38.7x compared to the industry average of 18.5x. Despite recent corporate moves like the Sweetwater …

Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT

Definium Therapeutics announced positive topline results from its Phase 3 Voyage trial for DT120 ODT in generalized anxiety disorder, meeting all primary and secondary endpoints with significant efficacy and a favorable safety profile. This milestone, achieved with its LSD-based oral dissolving tablet which holds …

Tuniu Corp (TOUR) CEO updates 1.98M-share option expiration terms

Tuniu Corp's CEO, Dunde Yu, has amended an existing stock option for 1.98 million Class A Ordinary Shares, extending its expiration date by one year from August 19, 2026, to August 19, 2027. This technical amendment, reported via Dragon Rabbit Capital Limited, involved a …

RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating

RBC Capital Markets has raised its price target for Definium Therapeutics, Inc. (DFTX) to $66 from $57, while maintaining an "Outperform Speculative Risk" rating. This adjustment comes after Definium Therapeutics announced positive Phase 3 study results for its lead candidate, DT120 ODT, in treating …

Canaccord raises Definium Therapeutics price target on trial data

Canaccord Genuity increased its price target for Definium Therapeutics (NASDAQ:DFTX) to $64 from $58, maintaining a Buy rating, after positive Phase 3 trial results for DT120 in generalized anxiety disorder. The trial showed DT120 significantly improved Hamilton-Anxiety scores with rapid onset and good tolerability. …

Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study

Definium Therapeutics announced positive top-line results from its Phase III Voyage study for DT120 ODT in generalized anxiety disorder (GAD), meeting its primary and all key secondary endpoints with rapid and durable improvements in anxiety symptoms. The treatment, a single 100 mcg dose, showed …

Royal Bank of Canada Purchases 179,418 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Royal Bank of Canada significantly increased its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 479.2% in the first quarter, acquiring 179,418 additional shares. This brings their total holdings to 216,861 shares, valued at approximately $4.9 million. Despite the substantial purchase, …

Enterprise value to revenue forward of Sprott Physical Uranium Trust – NEO:U.UN